Effect of chromium niacinate and chromium picolinate supplementation on lipid peroxidation, TNF-α, IL-6, CRP, glycated hemoglobin, triglycerides, and cholesterol levels in blood of streptozotocin-treated diabetic rats

Free Radical Biology and Medicine

Volumn 43, Issue 8, 2007, Pages 1124-1131

  Jain, Sushil K ^a   Rains, Justin L ^a   Croad, Jennifer L ^a  

^a Louisiana State University Health Sciences Center at Shreveport   (United States)

Author keywords

Chromium; Diabetes; Glycemia; Oxidative stress; Proinflammatory cytokines; Vascular inflammation

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; CHROMEMATE; CHROMIUM DERIVATIVE; CHROMIUM NIACINATE; CHROMIUM PICOLINATE; GLYCOSYLATED HEMOGLOBIN; INTERLEUKIN 6; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANESTHESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; INFLAMMATION; LIPID PEROXIDATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; RISK ASSESSMENT; STREPTOZOCIN DIABETES; SUPPLEMENTATION;

ANIMALS; C-REACTIVE PROTEIN; CHOLESTEROL; CHROMIUM; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; INTERLEUKIN-6; LIPID PEROXIDATION; MALE; NICOTINIC ACIDS; ORGANOMETALLIC COMPOUNDS; OXIDATIVE STRESS; PICOLINIC ACIDS; RATS; RATS, SPRAGUE-DAWLEY; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

RATTUS;

EID: 34548516394     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2007.05.019     Document Type: Article

References (69)

1. Rader D.J. Inflammatory markers of coronary risk. N. Engl. J. Med. 343 (2000) 1179-1182
2. Kern P.A., Ranganathan S., Li C., et al. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am. J. Physiol.: Endocrinol. Metab. 280 (2001) E745-E751
3. Andreozzi F., Laratta E., Cardellini M., et al. Plasma interleukin-6 levels are independently associated with insulin secretion in a cohort of Italian-Caucasian nondiabetic subjects. Diabetes 55 (2006) 2021-2024
4. Rui L., Aguirre V., Kim J.K., Shulman G.I., Lee A., Corbould A., Dunaif A., and White M.F. Insulin/IGF-1 and TNF- stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways. J. Clin. Invest. 107 (2001) 181-189
5. Devaraj S., and Jialal I. Antioxidants and vitamins to reduce cardiovascular disease. Curr. Atheroscler. Rep. 2 (2000) 342-351
6. Singh U., Devraj S., and Jialal I. Vitamin E, oxidative stress and inflammation. Annu. Rev. Nutr. 25 (2005) 151-174
7. Cavallo M.G., Pozzilli P., Bird C., Wadhwa M., Meager A., Visalli N., Gearing A.J., Andreani D., and Thorpe R. Cytokines in sera from insulin-dependent diabetic patients at diagnosis. Clin. Exp. Immunol. 86 (1991) 256-259
8. Jain S.K., Kannan K., Lim G., Matthew-Greer J., McVie R., and Bocchini J.A. Elevated blood interleukin-6 levels in hyperketonemic type 1 diabetic patients and secretion by acetoacetate-treated cultured U937 monocytes. Diabetes Care 26 (2003) 2139-2143
9. Hussain M.F., Peakman M., Gallati H., Lo S.S.S., Hawa M., Viberti G.C., Watkins P.J., Leslie R.D.G., and Vergani D. Elevated serum levels of macrophage-derived cytokines precede and accompany the onset of IDDM. Diabetologia 39 (1996) 60-69
10. Jain S.K., Kannan K., Lim G., McVie R., and Bocchini J.A. Hyperketonemia increases TNF-α secretion in cultured U937 monocytes and type-1 diabetic patients. Diabetes 51 (2002) 2287-2293
11. Halse R., Pearson S.L., McCormack J.G., Yeaman S.J., and Taylor R. Effects of tumor necrosis factor-a on insulin action in cultured human muscle cells. Diabetes 50 (2001) 1102-1109
12. Saghizadesh M., Ong J.M., Garvey W.T., Henry R.R., and Kern P.A. The expression of TNF-a by human muscle. Relationship to insulin resistance. J. Clin. Invest. 97 (1996) 1111-1116
13. Vincent J.B. Mechanisms of chromium action: low-molecular weight chromium-binding substance. J. Am. Coll. Nutr. 18 (1999) 6-12
14. Cefalu W.T., and Hu F.B. Role of chromium in human health and in diabetes. Diabetes Care 27 (2004) 2741-2751
15. Anderson R.A., Cheng N., Bryden N.A., Polansky M.M., Cheng N., Chi J., and Feng J. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes 46 (1997) 1786-1791
16. Lamson D.M., and Plaza S.M. The safety and efficacy of high-dose chromium. Altern. Med. Rev. 7 (2002) 218-235
17. Lee N.A., and Reasner C.A. Beneficial effect of chromium supplementation on serum triglyceride levels in NIDDM. Diabetes Care 17 (1994) 1449-1452
18. Offenbacher E.G., and Pi-Sunyer F.X. Beneficial effect of chromium-rich yeast on glucose tolerance and blood lipids in elderly subjects. Diabetes 29 (1980) 919-925
19. Mossop R.T. Effects of chromium III on fasting blood glucose, cholesterol and cholesterol HDL levels in diabetics. Cent. Afr. J. Med. 29 (1983) 80-82
20. Cheng N., Zhu X., Shi H., Wu W., Chi J., Cheng J., and Anderson R.A. Follow-up survey of people in china with type 2 diabetes mellitus consuming supplemental chromium. J. Trace Elem. Exp. Med. 12 (1999) 55-60
21. Abraham A.S., Brooks B.A., and Eylath U. Chromium and cholesterol-induced atherosclerosis in rabbits. Ann. Nutr. Metab. 35 (1991) 203-207
22. Jeejeebhoy K.N., Chu R.C., Marliss E.B., Greenberg G.R., and Bruce-Robertson A. Chromium deficiency, glucose intolerance, and neuropathy reversed by chromium supplementation in a patient receiving long-term total parenteral nutrition. Am. J. Clin. Nutr. 30 (1977) 531-538
23. Machalinski B., Walczak M., Syrenicz A., Machalinska A., Grymula K., Stecewicz I., Wiszniewska B., and Dabkowska E. Hypoglycemic potency of novel trivalent chromium in hyperglycemic insulin-deficient rats. J. Trace Elem. Med. Biol. 20 (2006) 33-39
24. Nakhoul F., Abassi Z., Morgan M., Sussan S., and Mirsky N. Inhibition of diabetic nephrophathy in rats by an oral antidiabetic material extracted from yeast. J. Am. Soc. Nephrol. 17 (2006) S127-S131
25. Clodfelder B.J., Gullick B.M., Lukaski H.C., Neggers Y., and Vincent J.B. Oral administration of the biomimetic [Cr3O(O2CCH2CH3)6(H2O)3]+ increases insulin sensitivity and improves blood plasma variables in healthy and type 2 diabetic rats. Biol. Inorg. Chem. 10 (2005) 119-130
26. Shinde U.A., Sharma G., Xu Y.J., Dhalla N.S., and Goyal R.K. Insulin sensitizing action of chromium picolinate in various experimental models of diabetes mellitus. J. Trace Elem. Med. Biol. 18 (2004) 23-32
27. Shinde U.A., Sharma G., Xu Y.J., Dhalla N.S., and Goyal R.K. Anti-diabetic activity and mechanism of action of chromium chloride. Exp. Clin. Endocrinol. Diabetes 112 (2004) 248-252
28. Kim D.S., Kim T.W., and Kang J.S. Chromium picolinate supplementation improves insulin sensitivity in Goto-Kakizaki diabetic rats. J. Trace Elem. Med. Biol. 17 (2004) 243-247
29. Cefalu W.T., Wang Z.Q., Zhang X.H., Baldor L.C., and Russell J.C. Oral chromium picolinate improves carbohydrate and lipid metabolism and enhances skeletal muscle Glut-4 translocation in obese, hyperinsulinemic (JCR-LA corpulent) rats. J. Nutr. 132 (2002) 1107-1114
30. Yoshimoto S., Sakamoto K., Wakabayashi I., and Masui H. Effect of chromium administration on glucose tolerance in stroke-prone spontaneously hypertensive rats with streptozotocin-induced diabetes. Metabolism 41 (1992) 636-642
31. Racek J., Trefil L., Rajdl D., Mudrova V., Hunter D., and Senft V. Influence of chromium-enriched yeast on blood glucose and insulin variables, blood lipids, and markers of oxidative stress in subjects with type 2 diabetes mellitus. Biol. Trace Elem. Res. 109 (2006) 215-230
32. Mita Y., Ishihara K., Fukuchi Y., Fukuva Y., and Yasumoto K. Supplementation with chromium picolinate recovers renal Cr concentration and improves carbohydrate metabolism and renal function in type 2 diabetic mice. Biol. Trace Elem. Res. 105 (2005) 229-248
33. Vinson J.A., Mandarano M.A., Shuta D.L., Bagchi M., and Bachi D. Beneficial effects of a novel IH636 grape seed proanthocyanidin extract and a niacin-bound chromium in a hamster atherosclerosis model. Mol. Cell. Biochem. 240 (2002) 99-103
34. Rink C., Roy S., Khanna S., Rink T., Bagchi D., and Sen C.K. Transcriptome of the subcutaneous adipose tissue in response to oral supplementation of type 2 Leprdb obese diabetic mice with niacin-bound chromium. Physiol. Genomics 27 (2007) 279-370
35. Martin J., Wang Z.Q., Zhang X.H., Wachtel D., Volaufova J., Matthews D.E., and Cefalu W.T. Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. Diabetes Care 29 (2006) 1826-1832
36. Vrtovic M., Vertovec B., Briski A., Kocijancic A., Anderson R.A., and Radovancevic B. Chromium supplementation shortenes QTc interval duration in patients with type 2 diabetes mellitus. Am. Heart J. 149 (2005) 632-636
37. 3 improves insulin responsiveness and reduces whole body glucose tolerance. FEBS Lett. 579 (2005) 1458-1464
38. Wang Z.Q., Zhang X.H., Russel J.C., Hulver M., and Cefalu W.T. Chromium picolinate enhances skeletal muscle cellular insulin siganaling in vivo in obese, insulin-resistant JCR:LA-cp Rats. J. Nutr. 136 (2006) 415-420
39. Chen G., Liu P., Pattar G.R., Tackett L., Bhonagiri P., Strawbridge A.B., and Elmendorf J.S. Chromium activates glucose transporter 4 trafficking and enhances insulin-stimulated glucose transport in 3T3-L1 adipocytes via a cholesterol-dependent mechanism. Mol. Endocrinol. 20 (2006) 857-870
40. Pattar G.R., Tackett L., Liu P., and Elmendorf J.S. Chromium picolinate positively influences the glucose transporter system via affecting cholesterol homeostasis in adipocytes cultured under hyperglycemic diabetic conditions. Mutat. Res. 610 (2006) 93-100
41. Jain S.K., and Kannan K. Chromium chloride inhibits oxidative stress and TNF-α secretion caused by exposure to high glucose in cultured monocytes. Biochem. Biophys. Res. Commun. 289 (2001) 687-691
42. Jain S.K., and Lim G. Chromium chloride inhibits TNF-α and IL-6 secretion in isolated human blood monoclear cells exposed to high glucose. Horm. Metab. Res. 38 (2006) 60-62
43. Jain S.K., McVie R., Duett J., and Herbst J.J. Erythrocyte membrane lipid peroxidation and glycosylated hemoglobin in diabetes. Diabetes 38 (1989) 1539-1543
44. Esterbauer H., Lang J., Zadravec S., and Slater T. Detection of malonaldehyde by high-performance liquid chromatography. Methods Enzymol. 105 (1984) 319-328
45. Guallar E.J.F., van't Veer P., Bode P., Riemersma R., Gomez-Aracena J., Kark J., Arab L., Kok F., and Martin-Moreno J.M. Teonail chromium and risk of myocardial infarction. Am. J. Epidemiol. 162 (2005) 157-164
46. Rajpathak S., Rimm E.B., Li T., Morris J.S., Stampfer M.J., Willett W.C., and Hu F.B. Lower toenail chromium in men with diabetes and cardiovascular disease compared with healthy men. Diabetes Care 27 (2004) 2211-2216
47. Jain S.K., Patel P., Rogier K., and Jain S.K. Trivalent chromium inhibits protein glycation and lipid peroxidation in high glucose treated erythrocytes. Antioxid. Redox Signal. 8 (2006) 238-241
48. 3. J. Inorg. Biochem. (2006) 1187-1193
49. Baud V., and Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol. 11 (2001) 372-377
50. Yudkin J.S., Stehouwer C.D., Emeis J.J., et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 972-978
51. Rosenstock M., Greenberg A.S., and Rudich A. Distinct long-term regulation of glycerol and non-esterified fatty acid release by insulin and TNF-alpha in 3T3-L1 adipocytes. Diabetologia 44 (2001) 55-62
52. Jialal I., Devraj S., and Venugopal S.K. C-reactive protein: risk marker or mediator in atherothrombosis. Hypertension 44 (2004) 6-11
53. Peraldi P., and Spiegelman B. TNF-alpha and insulin resistance: summary and future prospects. Mol. Cell. Biochem. 182 (1998) 169-175
54. Wellen K.E., and Hotamisligil G.S. Inflammation, stress, and oxidative stress. J. Clin. Invest. 115 (2005) 1111-1119
55. Carlson L.A. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J. Intern. Med. 258 (2005) 97-114
56. Kolovou G.D., Mikhalidis D.P., Adamopoulou E.N., Salpea K.D., Kafaltis N., Bilianou H.G., Malakos J., Pilatis N.D., Mykoniatis M., and Cokkinos D.V. The effect of nicotinic acid and alcohol co-administration in Wistar rats. Methods Find. Exp. Clin. Pharmacol. 27 (2005) 17-23
57. King G.L., and Loeken M.R. Hyperglycemia-induced oxidative stress in diabetic complications. Histochem. Cell Biol. 122 (2004) 333-338
58. Jay D., Hitomi H., and Griendling K.K. Oxidative stress and diabetic cardiovascular complications. Free Radic. Biol. Med. 40 (2006) 183-192
59. Jain S.K., Kannan K., and Lim G. Ketosis (acetoacetate) can generate oxygen radicals and cause increased lipid peroxidation and growth inhibition in human endothelial cells. Free Radic. Biol. Med. 25 (1998) 1083-1088
60. Jain S.K., and McVie R. Hyperketonemia can increase lipid peroxidation and lower glutathione levels in human erythrocytes in vitro and in type 1 diabetic patients. Diabetes 48 (1999) 555-1850
61. Jain S.K. Hyperglycemia can cause membrane lipid peroxidation and osmotic fragility in human red blood cells. J. Biol. Chem. 264 (1989) 21340-21345
62. Guha M., Bai W., Nadler J.L., and Natarajan R. Molecular mechanisms of tumor necrosis factor a gene expression in monocytic cells via hyperglycemia-induced oxidant stress-dependent and -independent pathways. J. Biol. Chem. 275 (2000) 17728-17739
63. Yerneni K.K., Bai W., Khan B.V., Medford R.M., and Natarajan R. Hyperglycemia-induced activation of nuclear transcription factor kappaB in vascular smooth muscle cells. Diabetes 48 (1999) 855-864
64. Jain S.K., McVie R., Jackson R., Levine S.N., and Lim G. Effect of hyperketonemia on lipid peroxidation levels of plasma in diabetic patients. Diabetes Care 22 (1999) 171-1175
65. Brownlee M. The pathogenesis of diabetic complications: a unifying mechanism. Diabetes 54 (2005) 1615-1625
66. Kaneto H., Matsuoka T., Nakatani Y., Kawamori D., Matsuhisa M., and Yamasaki Y. Oxidative stress and the JNK pathway in diabetes. Curr. Diabetes Rev. 1 (2005) 65-72
67. Lei Y.-C., Hwang J.-S., Chan C.-C., Lee C.-T., and Cheng T.-J. Enhanced oxidative stress and endothelial dysfunction in streptozotocin-diabetic rats exposed to fine particles. Environ. Res. 99 (2005) 335-343
68. Cho W.C., Yip T.-T., Chung W.-S., Leung A.W., Cheng C.H., and Yue K.K. Differentialexpression of proteins in kidney, eye, aorta, and serum of diabetic and non-diabetic rats. J. Cell. Biochem. 99 (2006) 256-268
69. National Research Council, Food and Nutrition Board. Recommended Dietary Allowances. 10th edition (1989), National Academy Press, Washington, DC